Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company's main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303.